- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03625752
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
Optimization of Non-Invasive Brain Stimulation for Diabetic Neuropathy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Active stimulation will be compared with compared to SHAM stimulation in DNP patients.
20 DNP patients, 10 per group, receive stimulation or sham for 5 consecutive days, 20 min/day, followed by 2, 4, and 6 weeks post-therapy. 9 visits plus screening/baseline (total 10 visits).
Subsequently, 40 DNP patients will be enrolled, 20 per group, giving 5 consecutive days, 20 min/day, followed by 2 weeks of bi-weekly stimulation or sham for 20 min/day (total stimulations n=9) and follow-ups at 2, 4, 6, & 8 weeks post-stim): 13 visits plus screening/ baseline (total 14 visits).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Megan O'Neill Miller
- Phone Number: 216-844-4720
- Email: megan.miller3@uhhospitals.org
Study Contact Backup
- Name: Kimberly Puskus
- Phone Number: (216) 844-3194
- Email: kimberly.puskus@uhhospitals.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Ciro Ramos Estebanez
-
Contact:
- Ciro Ramos Estebanez, MD., Ph.D.
- Email: cramoses@uic.edu
-
Principal Investigator:
- Ciro Ramos Estebanez, MD., Ph.D.
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-1716
- Recruiting
- University Hospitals Cleveland Medical Center/ Dahms Clinical Research Unit
-
Contact:
- Ciro Ramos Estebanez, MD, PhD
- Email: cramoses@icloud.com
-
Contact:
- Jillian Russell, MSN, RN-BC
- Phone Number: 216-844-4901
- Email: Jillian.Russell@uhhospitals.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to provide informed consent to participate in the study.
- Subjects between 40 to 80 years old.
- Having diabetic neuropathic pain, involving at least 1 foot, with existing pain for at least 6 months, and having pain on at least half the days in the past 6 months with an average of at least a 4 on a 0-10 VAS scale).
- Having pain resistant to common analgesics and medications for first-line therapy of chronic pain such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, Codeine, etc.
- Must have the ability to feel pain as self-reported.
Exclusion Criteria:
- Subject is pregnant.
- Contraindications to tDCS in conjunction with TUS, i.e. metallic implant in the brain or implanted brain medical devices
- History of alcohol or drug abuse within the past 6 months as self-reported.
- Use of carbamazepine within the past 6 months as self-reported.
- Suffering from severe depression (with a PHQ 9 score of ≥ 10).
- History of neurological disorders as self-reported.
- History of unexplained fainting spells as self-reported.
- History of severe head injury resulting in more than a momentary loss of consciousness as self-reported.
- History of neurosurgery as self-reported.
- Unstable pain (defined as pain intensities that vary by more than 4 points on 0-10 VAS scale over the 1-week period of trial run-in).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Comparator: Active tDCS + Active TUS
Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
|
Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA.
The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area.
In the sham group, the tDCS device will not be active for the full 20 minutes.
Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS.
During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
|
Sham Comparator: Sham
Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
|
Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA.
The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area.
In the sham group, the tDCS device will not be active for the full 20 minutes.
Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS.
During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in pain as measured by the Visual Analog Scale (VAS)
Time Frame: Measured for approximately 3 months
|
The scale will assess a patient's pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable).
Changes in VAS for Pain will be measured to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in reducing pain of subjects with diabetic neuropathic pain.
|
Measured for approximately 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Verbal Rating Scale (VRS) for Pain
Time Frame: Measured for approximately 3 months
|
The VRS for Pain is a categorical scale of pain with categories: none, mild, moderate, severe pain intensity.
Changes in VRS for Pain will be measured in order to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction.
with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in reducing pain of subjects with diabetic neuropathic pain.
|
Measured for approximately 3 months
|
Changes in Conditional Pain Modulation
Time Frame: Measured for approximately 3 months
|
Changes in Conditional Pain Modulation (CPM) will be measured in order to determine whether anodal transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) (applied in a diagnostic mode) is effective in increasing the pain pressure threshold in subjects with diabetic neuropathic pain.
|
Measured for approximately 3 months
|
Changes in Visual Analog Scalefor Mood (VAMS)
Time Frame: Measured for approximately 3 months
|
The VAS for Mood will investigate Anxiety, Depression, Stress, and Sleepiness. The Subscales are as follows: The anxiety scale will assess a patient's anxiety on a scale from 0 (not anxious) to 10 (very anxious). The depression scale will assess a patient's depression on a scale from 0 (not depressed) to 10 (very depressed). The stress scale will assess a patient's stress on a scale from 0 (not stressed) to 10 (very stressed). The sleepiness scale will assess a patient's depression on a scale from 0 (not sleepy) to 10 (very sleepy). |
Measured for approximately 3 months
|
Montreal Cognitive Assessment
Time Frame: Measured for approximately 3 months
|
The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition.
Scores range from lowest being 0 to highest being 30.
|
Measured for approximately 3 months
|
4-choice reaction time
Time Frame: Measured for approximately 3 months
|
This is an attentional task that measures the time for a subject response to stimuli (in seconds) with shorter times being better.
|
Measured for approximately 3 months
|
N-back tests
Time Frame: Measured for approximately 3 months
|
Assesses registration and immediate recall on a scale of the number of items correctly responded to
|
Measured for approximately 3 months
|
Electroencephalography
Time Frame: Measured for approximately 3 months
|
Investigators will measure electroencephalogram (EEG) electrical activity (EEG amplitude and EEG frequency) as function of time.
|
Measured for approximately 3 months
|
Walking test
Time Frame: Measured for approximately 3 months
|
The investigators will measure if there are changes in the walking speed, gait asymmetry, stride length, and walking smoothness of the subject from the beginning of the study to the end
|
Measured for approximately 3 months
|
Functional reach test
Time Frame: Measured for approximately 3 months
|
The investigators will measure changes in subjects ability to complete the functional reach test across the duration of study.
|
Measured for approximately 3 months
|
Study 36-Item Short Form (SF-36)
Time Frame: Measured for approximately 3 months
|
This is a health survey using a scale from 0 (worst) to 100 (best)
|
Measured for approximately 3 months
|
Patient Health Questionnaire (PHQ-9)
Time Frame: Measured for approximately 3 months
|
This questionnaire screens for depression with a score of 0 (best) to 27 (worst)
|
Measured for approximately 3 months
|
American Pain Foundation Pain and Medication Diary
Time Frame: Measured for approximately 3 months
|
The pain sub-scale measures pain intensity from 0 (best) to 10 (worst)
|
Measured for approximately 3 months
|
Multidimensional Pain Inventory (MPI)
Time Frame: Measured for approximately 3 months
|
This pain scale measures aspects of pain from 0 (best) to 6 (worst)
|
Measured for approximately 3 months
|
Brief Pain Inventory-DPN
Time Frame: Measured for approximately 3 months
|
This pain scale measures aspects of pain from 0 (no pain) to 10 (worst)
|
Measured for approximately 3 months
|
Adverse events
Time Frame: Measured for approximately 3 months
|
At each session after stimulation begins, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 5-point scale (0 being best and 5 worst).
The scale will also be administered at the follow-up.
|
Measured for approximately 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Salim Hayek, MD PhD, University Hospitals Cleveland Medical Center/ Case Western Reserve University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20180314-2/20201584
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Neuropathies
-
AstraZenecaCompletedDiabetic Neuropathy, Painful; Diabetic NeuropathiesUnited States
-
WinSanTor, IncCompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, PainfulCanada
-
Maastricht University Medical CenterCompletedPainful Diabetic Neuropathy | Diabetic Neuropathies, Painful | Neuralgia, DiabeticNetherlands
-
Helixmith Co., Ltd.CompletedPainful Diabetic NeuropathiesUnited States, Korea, Republic of
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
Corporacion Parc TauliCompletedDiabetic Neuropathy | Diabetic Nerve Problems | Diabetic Complications NeurologicalPakistan
-
University Medical Centre LjubljanaUnknown
-
Timothy J. Best Medicine Professional CorporationThe Physicians' Services Incorporated FoundationCompleted
-
AbbVie (prior sponsor, Abbott)CompletedDiabetic Neuropathies | Diabetic Neuropathy, Painful | Diabetic Polyneuropathy | Diabetic Neuralgia | Neuralgia, DiabeticUnited States, Canada, France, Germany, Italy, Mexico, Puerto Rico
-
Eva PharmaMARC-CRORecruiting
Clinical Trials on Active Comparator: Active tDCS + Active TUS
-
Case Western Reserve UniversityHighland Instruments, Inc.Recruiting
-
Spaulding Rehabilitation HospitalHighland Instruments, Inc.RecruitingParkinson DiseaseUnited States
-
Case Western Reserve UniversityHighland Instruments, Inc.RecruitingDiabetic Neuropathies | Chronic PainUnited States
-
University Health Network, TorontoRecruitingParkinson Disease | Dystonia | Essential TremorCanada
-
Duke UniversityEnrolling by invitationLong COVID | Long Covid19 | Long Covid-19United States
-
Duke UniversityEnrolling by invitationLong COVID | Long Covid19 | Long Covid-19United States
-
University Health Network, TorontoActive, not recruitingParkinson Disease | DystoniaCanada
-
University of New MexicoNational Institutes of Health (NIH); National Institute of General Medical... and other collaboratorsRecruitingStroke | AphasiaUnited States
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedMigraineUnited States
-
The University of Texas at DallasActive, not recruiting